We found that the validity of the optimized CanPatrol CTC-enrichment technique was confirmed by the detection of CTCs from 62 of the 80 (77.5%) HCC patients and by the detection of Twist+ CTCs from 54 of the 80 (67.5%) HCC patients. The gene discussed is TWIST1; the disease is hepatocellular carcinoma.